Survivin Hakkında Bilinenler: Survivin İle İlgili Türkiye’de Yapılmış Olan Çalışmalar

Öz

İnsanlarda 3 intron ve 4 ekzondan meydana gelen Survivin geni kromozomun 17q25 bölgesinde yer alan 14,7 kb uzunluğunda olan ve 142 aminoasitlik, 16,5 KD ağırlığında proteini kodlayan bir gendir. Survivin; akciğer, böbrek, cilt, endometriyum, mide, kolon, meme, prostat, yumurtalık, lösemi, baş ve boyun kanseri gibi çeşitli kanser türlerinde aşırı ifade edilmesi, histopatolojisi ve promotör bölgesindeki polimorfizmler sebebiyle birçok kez araştırmacılar tarafından çalışılmış olan ve apoptoz inhibitör ailesinin üyesi olan bir gendir. Biz bu derlemede Survivin ile ilgili bilinenleri ve Türk popülasyonunda bugüne kadar Survivin ile yapılan çalışmaları Türkçe olarak okuyucuya sunmaya çalıştık. Böylece literatürdeki önemli bir eksiklik giderilebileceği gibi, araştırmacılara bundan sonra yapılacak olan çalışmalarda bu derlemenin yol göstereceği kanaatindeyiz.

Anahtar Kelimeler

• Survivin; BIRC5 protein; polimorfizm; kanser; Türk populasyonu

-

Öz

The human Survivin gene located on chromosome 17q25, consist of 4 exon and 3 intron spanning 14.7 kb and it codes16.5 KD weight protein which has 142 aminoacids. Survivin has been studied many times because of its overexpressionin several types of cancer including lung, kidney, skin, endometrium, stomach, colon, breast, prostate, over, hematologic,head and neck cancers, histopathology features and polymorphisms in the promoter region which belongs to the inhibitörof apoptosis gene family by researchers. In this literature rewiev, we presented to readers the known about survivin geneand all published survivin studies relevant Turkish population in Turkish up to the present. Therefore, an importantdeficiency can be eliminated in literature and we believe that this review will lead to researchers in studies to be madeafter

Anahtar Kelimeler

• Survivin; BIRC5 protein; polymorphism; cancer; Turkish population

Kaynakça

1. Han CH, Wei Q, Lu KK, Liu Z, Mills GB, Wang L-E. Polymorphisms in the survivin promoter are associated with age of onset of ovarian cancer. International journal of clinical and experimental medicine. 2009; 2(4): 289.
2. Altieri DC, Marchisio P. Survivin apoptosis: an interloper between cell death and cell proliferation in cancer. Laboratory investigation; a journal of technical methods and pathology. 1999; 79(11): 1327.
3. Altieri DC. The case for survivin as a regulator of microtubule dynamics and cell-death decisions. Current opinion in cell biology. 2006; 18(6): 609-15.
4. Giodini A, Kallio MJ, Wall NR, Gorbsky GJ, Tognin S, Marchisio PC, et al. Regulation of microtubule stability and mitotic progression by survivin. Cancer research. 2002; 62(9): 2462-7.
5. Wang Y-H, Chiou H-Y, Lin C-T, Hsieh H-Y, Wu C-C, Hsu C-D, et al. Association between survivin gene promoter− 31 C/G polymorphism and urothelial carcinoma risk in Taiwanese population. Urology. 2009; 73(3): 670-4.
6. Gazouli M, Tzanakis N, Rallis G, Theodoropoulos G, Papaconstantinou I, Kostakis A, et al. Survivin-31G/C promoter polymorphism and sporadic colorectal cancer. International journal of colorectal disease. 2009; 24(2): 145-50.
7. Andric M, Nikolic N, Boskovic M, Milicic B, Skodric S, Basta Jovanovic G, et al. Survivin gene promoter polymorphism-31G/C as a risk factor for keratocystic odontogenic tumor development. European journal of oral sciences. 2012; 120(1): 9-13.
8. Nicholson DW, Thornberry NA. Caspases: killer proteases. Trends in biochemical sciences. 1997; 22(8): 299-306.

9. Li Y-H, Wang C, Meng K, Chen L-B, Zhou X-J. Influence of survivin and caspase-3 on cell apoptosis and prognosis in gastric carcinoma. World Journal of Gastroenterology. 2004; 10(13): 1984-8.
10. Adida C, Crotty PL, McGrath J, Berrebi D, Diebold J, Altieri DC. Developmentally regulated expression of the novel cancer anti-apoptosis gene survivin in human and mouse differentiation. The American journal of pathology. 1998; 152(1): 43.
11. Muzio LL, Pannone G, Staibano S, Mignogna M, Rubini C, Mariggio M, et al. Survivin expression in oral squamous cell carcinoma. British journal of cancer. 2003; 89(12): 2244-8.
12. Eröz R, Karataş A, Alkoç OA, Baltaci D, Oktay M, Çolakoğlu S. Apoptozis hakkında bilinenler (literatür taraması). Duzce Medical Journal. 2012; 14(2): 87- 101.
13. Altieri DC. The molecular basis and potential role of survivin in cancer diagnosis and therapy. Trends in molecular medicine. 2001; 7(12): 542-7.
14. Yamamoto T, Tanigawa N. The role of survivin as a new target of diagnosis and treatment in human cancer. Medical Electron Microscopy. 2001; 34(4): 207-12.
15. Mohatka C, Wenzel M, Springer E, Gabbert H, Gerharz C. Survivin-∆ Ex3 and Survivin-2B: two novel splice variants of the apoptosis inhibitor survivin with different antiapoptotic properties. Cancer Res. 1999; 59(24): 6097-102.
16. Frost M, Jarboe EA, Orlicky D, Gianani R, Thompson LC, Enomoto T, et al. Immunohistochemical localization of survivin in benign cervical mucosa, cervical dysplasia, and invasive squamous cell carcinoma. American journal of clinical pathology. 2002; 117(5): 738-44.
17. Altieri DC. Validating survivin as a cancer therapeutic target. Nature Reviews Cancer. 2003; 3(1): 46-54.
18. Schimmer AD. Inhibitor of apoptosis proteins: translating basic knowledge into clinical practice. Cancer research. 2004; 64(20): 7183-90.
19. Shinohara ET, Gonzalez A, Massion PP, Chen H, Li M, Freyer AS, et al. Nuclear survivin predicts recurrence and poor survival in patients with resected nonsmall cell lung carcinoma. Cancer. 2005; 103(8): 1685-92.
20. Grossman D, Mcniff JM, Li F, Altieri DC. Expression of the apoptosis inhibitor, survivin, in nonmelanoma skin cancer and gene targeting in a keratinocyte cell line. Laboratory investigation; a journal of technical methods and pathology. 1999; 79(9): 1121-6.
21. Kawasaki H, Toyoda M, Shinohara H, Okuda J, Watanabe I, Yamamoto T, et al. Expression of survivin correlates with apoptosis, proliferation, and angiogenesis during human colorectal tumorigenesis. Cancer. 2001; 91(11): 2026-32.
22. Muzio LL, Pannone G, Leonardi R, Staibano S, Mignogna M, De Rosa G, et al. Survivin, a potential early predictor of tumor progression in the oral mucosa. Journal of dental research. 2003; 82(11): 923- 8.
23. Hofmann H-S, Simm A, Hammer A, Silber R-E, Bartling B. Expression of inhibitors of apoptosis (IAP) proteins in non-small cell human lung cancer. Journal of cancer research and clinical oncology. 2002; 128(10): 554-60.
24. Mirza A, McGuirk M, Hockenberry TN, Wu Q, Ashar H, Black S, et al. Human survivin is negatively regulated by wild-type p53 and participates in p53- dependent apoptotic pathway. Oncogene. 2002; 21(17): 2613-22.
25. Nakano J, Huang C-L, Liu D, Ueno M, Sumitomo S, Yokomise H. Survivin gene expression is negatively regulated by the p53 tumor suppressor gene in non- small cell lung cancer. International journal of oncology. 2005; 27(5): 1215-21.
26. Tamm I, Wang Y, Sausville E, Scudiero DA, Vigna N, Oltersdorf T, et al. IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer research. 1998; 58(23): 5315-20.
27. Wang Y-Q, Zhang H-H, Liu C-L, Wu H, Wang P, Xia Q, et al. Enhancement of survivin-specific anti-tumor immunity by adenovirus prime protein-boost immunity strategy with DDA/MPL adjuvant in a murine immunopharmacology. 2013; 17(1): 9-17. model. International
28. Hirota S, Ohashi A, Nishida T, Isozaki K, Kinoshita K, Shinomura Y, et al. Gain-of-function mutations of platelet-derived growth factor receptor α gene in gastrointestinal stromal tumors. Gastroenterology. 2003; 125(3): 660-7.
29. Konturek PC, Konturek SJ, Pierzchalski P, Bielanski W, Duda A, Marlicz K, et al. Cancerogenesis in Helicobacter pylori infected stomach-role of growth factors, apoptosis and cyclooxygenases. Medical Science Monitor. 2001; 7(5): 1092-107.
30. Johnson M, Howerth E. Survivin: a bifunctional inhibitor of apoptosis protein. Veterinary Pathology Online. 2004; 41(6): 599-607.
31. Sun C, Cai M, Gunasekera AH, Meadows RP, Wang H, Chen J, et al. NMR structure and mutagenesis of the inhibitor-of-apoptosis protein XIAP. Nature. 1999; 401(6755): 818-22.
32. Islam A, Kageyama H, Takada N, Kawamato T, Takayasu H, Isogai E, et al. High expression of Survivin, mapped to 17q25, is significantly associated with poor prognostic factors and promotes cell survival in human neuroblastoma. Oncogene. 2000;
33. Kato J, Kuwabara Y, Mitani M, Shinoda N, Sato A, Toyama T, et al. Expression of survivin in esophageal cancer: correlation with the prognosis and response to chemotherapy. International journal of cancer. 2001; 95(2): 92-5.
34. Song KY, Jung CK, Park WS, Park CH. Expression of the antiapoptosis gene Survivin predicts poor prognosis of stage III gastric adenocarcinoma. Japanese journal of clinical oncology. 2009; 39(5): 290-6.
35. Nachmias B, Ashhab Y, Ben-Yehuda D, editors. The inhibitor of apoptosis protein family (IAPs): an emerging therapeutic target in cancer. Semin Cancer Biol. 2004; 14(4): 231-43.
36. Dai J, Jin G, Dong J, Chen Y, Xu L, Hu Z, et al. Prognostic significance of survivin polymorphisms on non-small cell lung cancer survival. Journal of Thoracic Oncology. 2010; 5(11): 1748-54.
37. Machtay M, Jeremic B, editors. Complex and controversial issues in locally advanced non-small cell lung carcinoma. Seminars in surgical oncology; 2003; 21(2): 128-37.
38. Deveraux QL, Reed JC. IAP family proteins— suppressors of apoptosis. Genes & development.
39. Asanuma K, Kobayashi D, Furuya D, Tsuji N, Yagihashi A, Watanabe N. A role for survivin in radioresistance of pancreatic cancer cells. Japanese Journal of Cancer Research. 2002; 93(9): 1057-62.
40. Okada E, Murai Y, Matsui K, Isizawa S, Cheng C, Masuda M, et al. Survivin expression in tumor cell nuclei is predictive of a favorable prognosis in gastric cancer patients. Cancer letters. 2001; 163(1): 109-16.
41. Monzó M, Rosell R, Felip E, Astudillo J, Sánchez JJ, Maestre J, et al. A novel anti-apoptosis gene: re- expression of survivin messenger RNA as a prognosis marker in non–small-cell lung cancers. Journal of Clinical Oncology. 1999; 17(7): 2100-4.
42. Lu C-D, Altieri DC, Tanigawa N. Expression of a novel antiapoptosis gene, survivin, correlated with tumor cell apoptosis and p53 accumulation in gastric carcinomas. Cancer Research. 1998; 58(9): 1808-12.
43. Tanaka K, Iwamoto S, Gon G, Nohara T, Iwamoto M, Tanigawa N. Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. Clinical Cancer Research. 2000; 6(1): 127-34.
44. Kappler M, Köhler T, Kampf C, Diestelkötter P, Würl P, Schmitz M, et al. Increased survivin transcript levels: an independent negative predictor of survival in soft tissue sarcoma patients. International journal of cancer. 2001; 95(6): 360-3.
45. Sarela A, Macadam R, Farmery S, Markham A, Guillou P. Expression of the antiapoptosis gene, survivin, predicts death from recurrent colorectal carcinoma. Gut. 2000; 46(5): 645-50.
46. Wagner M, Schmelz K, Wuchter C, Ludwig WD, Dörken B, Tamm I. In vivo expression of survivin and its splice variant survivin-2B: Impact on clinical outcome in acute myeloid leukemia. International journal of cancer. 2006; 119(6): 1291-7.
47. Otaki M, Hatano M, Kobayashi K, Ogasawara T, Kuriyama T, Tokuhisa T. Cell cycle-dependent regulation Biochimica et Biophysica Acta (BBA)-Gene Structure and Expression. 2000; 1493(1): 188-94. expression.
48. Li F, Altieri DC. The Cancer Antiapoptosis Mouse Survivin Gene Characterization of Locus and Transcriptional Requirements of Basal and Cell Cycle-dependent Expression. Cancer research. 1999; 59(13): 3143-51.
49. Dai C-H, Li J, Shi S-B, Yu L-C, Ge L-P, Chen P. Survivin and Smac gene expressions but not livin are predictors of prognosis in non-small cell lung cancer patients treated with adjuvant chemotherapy following surgery. Japanese journal of clinical oncology. 2010; 40(4): 327-35.
50. Xu Y, Fang F, Ludewig G, Jones G, Jones D. A mutation found in the promoter region of the human survivin gene is correlated to overexpression of survivin in cancer cells. DNA and cell biology. 2004; 23(7): 419-29.
51. Yazdani N, Sayahpour FA, Haghpanah V, Amiri P, Shahrabi-Farahani M, Moradi M, et al. Survivin gene polymorphism association with papillary thyroid carcinoma. Pathology-Research and Practice. 2012; 208(2): 100-3.
52. Yang L, Zhu H, Zhou B, Gu H, Yan H, Tang N, et al. The association between the survivin C-31G polymorphism and gastric cancer risk in a Chinese population. Digestive diseases and sciences. 2009; 54(5): 1021-8.
53. Upadhyay R, Khurana R, Kumar S, Ghoshal UC, Mittal B. Role of survivin gene promoter polymorphism (− 31G> C) in susceptibility and survival of esophageal cancer in northern India. Annals of surgical oncology. 2011; 18(3): 880-7.
54. Bayram S, Akkız H, Bekar A, Akgöllü E. The association between the survivin− 31G/C promoter polymorphism and hepatocellular carcinoma risk in a Turkish population. Cancer epidemiology. 2011; 35(6): 555-9.
55. Theodoropoulos GE, Michalopoulos NV, Panoussopoulos S-G, Taka S, Gazouli M. Effects of caspase-9 and survivin gene polymorphisms in pancreatic cancer risk and tumor characteristics. Pancreas. 2010; 39(7): 976-80.
56. Borbely A, Murvai M, Szarka K, Kónya J, Gergely L, Hernádi Z, et al. Survivin promoter polymorphism and cervical carcinogenesis. Journal of clinical pathology. 2007; 60(3): 303-6.
57. Altiparmak MD, Bilgiç Cİ, Dener NC, Gündüz E, Yenidünya S, Acar M, et al. The effect of survivin gene promoter polymorphism on breast cancer. Turkish Journal of Biology. 2014; 38(6): 858-66.
58. Aynaci E, Coskunpinar E, Eren A, Kum O, Oltulu YM, Akkaya N, et al. Association between survivin gene promoter -31G/C and -644C/T polymorphisms and non-small cell lung cancer. Genetics and molecular research: GMR. 2013; 12(3): 3975-82.
59. Aynaci E, Coskunpinar E, Eren A, Kum O, Musteri Oltulu Y, Akkaya N, et al. Survivin geni -625GC polimorfizminin Küçük Hücreli Dışı Akciğer. Journal of Cell and Molecular Biology. 2012; 10(1): 27-32.
60. Sun M, Lou W, Chun JY, Cho DS, Nadiminty N, Evans CP, et al. Sanguinarine suppresses prostate tumor growth and inhibits survivin expression. Genes & cancer. 2010; 1(3): 283-92.
61. Kaya S. Kolorektal kanserli olgularda oksidatif stresin araştırılması [Uzmanlık Tezi]. Edirne: Trakya Üniversitesi Tıp Fakültesi Biyokimya Anabilim Dali; 2010.
62. Lu B, Gonzalez A, Massion P, Shyr Y, Shaktour B, Carbone D, et al. Nuclear survivin as a biomarker for non-small-cell lung cancer. British journal of cancer.
63. Nakanishi K, Kawai T, Kumaki F, Hiroi S, Mukai M, Ikeda E. Survivin expression in atypical adenomatous hyperplasia of the lung. American journal of clinical pathology. 2003; 120(5): 712-9.
64. Akyurek N, Memis L, Ekinci O, Kokturk N, Ozturk C. Survivin expression in pre-invasive lesions and non-small cell lung carcinoma. Virchows Archiv : an international journal of pathology. 2006; 449(2): 164- 70.
65. Atikcan S, Unsal E, Demirag F, Koksal D, Yilmaz A. Correlation between survivin expression and prognosis in non-small cell lung cancer. Respiratory medicine. 2006; 100(12): 2220-6.
66. Smith SD, Wheeler MA, Plescia J, Colberg JW, Weiss RM, Altieri DC. Urine detection of survivin and diagnosis of bladder cancer. Jama. 2001; 285(3): 324- 8.
67. Dong D, Yang Y, Xue D, Feng X. [Expression of survivin mRNA of sputum and pleural effusions in human lung cancer]. Zhong nan da xue xue bao Yi xue ban= Journal of Central South University Medical sciences. 2006; 31(6): 848-52.
68. Gorgun D, Secik F, Midilli K, Akkaya V, Yildiz P. Diagnostic and prognostic significance of survivin levels in malignant pleural effusion. Respiratory medicine. 2013; 107(8): 1260-5.
69. Ulukaya E, Acilan C, Yilmaz M, Yilmaztepe-Oral A, Ari F, Zik B, et al. sFas levels increase in response to cisplatin-based chemotherapy in lung cancer patients. Cell biochemistry and function. 2010; 28(7): 565-70.
70. Derin D, Soydinc HO, Guney N, Tas F, Camlica H, Duranyildiz D, et al. Serum levels of apoptosis biomarkers, survivin and TNF-alpha in nonsmall cell lung cancer. Lung cancer. 2008; 59(2): 240-5.
71. Baykara O, Bakir B, Buyru N, Kaynak K, Dalay N. Amplification of chromosome 8 genes in lung cancer. Journal of Cancer. 2015; 6(3): 270-5.
72. Dogan I, Cumaoglu A, Aricioglu A, Ekmekci A. Inhibition of ErbB2 by herceptin reduces viability and survival, induces apoptosis and oxidative stress in Calu-3 cell line. Molecular and cellular biochemistry. 2011; 347(1-2): 41-51.
73. Erpolat OP, Gocun PU, Akmansu M, Karakus E, Akyol G. High expression of nuclear survivin and Aurora B predicts poor overall survival in patients with head and neck squamous cell cancer. Strahlenther Onkol. 2012; 188(3): 248-54. doi: 10.1007/s00066- 011-0042-7. 85. Arafah B, Nasrallah M. Pituitary manifestations pathophysiology,
74. management. Endocrine-Related Cancer. 2001; 8(4): 287-305. and
75. Dellal FD, Niyazoglu M, Gorar S, Ademoglu E, Candan Z, Bekdemir H, et al. Serum Survivin Increases in Prolactinoma. Journal of clinical medicine research. 2015; 7(4): 248.
76. Zamparese R, Pannone G, Santoro A, Muzio LL, Corsi F, Pedicillo MC, et al. Survivin expression in renal cell carcinoma. Cancer investigation. 2008; 26(9): 929-35.
77. Lei Y, Geng Z, Guo-Jun W, He W, Jian-Lin Y. Prognostic significance of survivin expression in renal cell cancer and its correlation with radioresistance. Molecular and cellular biochemistry. 2010; 344(1-2): 23-31.
78. Ozcan A, Yigit N, Onguru O, Alp B, Ozaydin S. Survivin Expression in Renal Epithelial Tumors: It's Usage in the Differential Diagnosis of Eosinophilic Renal Epithelial Tumors. J Interdiscipl Histopathol. 2014; 2(2): 69-73.
79. Maxia C, Perra MT, Demurtas P, Minerba L, Murtas D, Piras F, et al. Relationship between the expression of cyclooxygenase-2 and survivin in primary pterygium. Mol Vis. 2009; 15: 458-63.
80. Barnes N, Haywood P, Flint P, Knox W, Bundred N. Survivin expression in in situ and invasive breast cancer relates to COX-2 expression and DCIS recurrence. British journal of cancer. 2006; 94(2): 253- 8.
81. Erkanli S, Bolat F, Kayaselcuk F, Demirhan B, Kuscu E. COX-2 and survivin are overexpressed and positively correlated in endometrial carcinoma. Gynecologic oncology. 2007; 104(2): 320-5.
82. U Yıldırım HE, A Kayıkcı, AF Sahin, AK Uzunlar and A Albayrak. Cyclooxygenase-2 and Survivin in Superficial Urothelial Carcinoma of the Bladder and Correlation with Intratumoural Microvessel Density. The Journal of International Medical Research. 2010; 38(5): 1689-99.
83. Baytekin F, Tuna B, Mungan U, Aslan G, Yorukoglu K. Significance of P-glycoprotein, p53, and survivin expression in renal cell carcinoma. Urologic oncology. 2011; 29(5): 502-7.
84. Ozcan A, Yavan I, Gunhan O. Immunohistochemical Characteristics of Cystic Odontogenic Lesions: A Comparative Study. Turk patoloji dergisi. 2015; 31(2): 104-10.
85. Tas F, Duranyildiz D, Argon A, Oguz H, Camlica H, Yasasever V, et al. Serum bcl-2 and survivin levels in melanoma. Melanoma research. 2004; 14(6): 543-6.
86. Yilmaz E, Koyuncuoglu M, Gorken IB, Okyay E, Saatli B, Ulukus EC, et al. Expression of matrix metalloproteinase-2 and survivin in endometrioid and nonendometrioid clinicopathologic significance. Journal of gynecologic oncology. 2011; 22(2): 89-96. cancers and
87. Erkanli S, Kayaselcuk F, Kuscu E, Bagis T, Bolat F, Haberal A, et al. Expression of survivin, PTEN and p27 in normal, hyperplastic, and carcinomatous endometrium. International Journal of Gynecological Cancer. 2006; 16(3): 1412-8.
88. Baykara M, Akkus M, Yildiz R, Gonul, II, Dursun A, Coskun U, et al. Survivin expression and its potential clinical significance in gastrointestinal stromal sarcoma. International immunopharmacology. 2011; 11(12): 2227-31.
89. Li F, Ambrosini G, Chu EY, Plescia J, Tognin S, Marchisio PC, et al. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature. 1998; 396(6711): 580-4.
90. Rödel C, Haas J, Groth A, Grabenbauer GG, Sauer R, Rödel F. Spontaneous and radiation-induced apoptosis in colorectal carcinoma cells with different intrinsic radiosensitivities: survivin as a radioresistance factor. International Journal of Radiation Oncology Biology Physics. 2003; 55(5): 1341-7.
91. Rödel F, Hoffmann J, Distel L, Herrmann M, Noisternig T, Papadopoulos T, et al. Survivin as a radioresistance factor, and prognostic and therapeutic target for radiotherapy in rectal cancer. Cancer research. 2005; 65(11): 4881-7.
92. Terzi C, Canda AE, Sagol O, Atila K, Sonmez D, Fuzun M, et al. Survivin, p53, and Ki-67 as predictors of histopathologic response in locally advanced rectal cancer treated with preoperative chemoradiotherapy. International journal of colorectal disease. 2008; 23(1): 37-45.
93. Budak M, Korpinar MA, Kalkan T, Tuncel H. Mutation detection in the promoter region of survivin gene on N-methyl-N-nitrosourea induced colon tumor model in experiment. Bratislava Medical Journal. 2014; 115(9): 554-6.
94. Adida C, Recher C, Raffoux E, Daniel MT, Taksin AL, Rousselot P, et al. Expression and prognostic significance of survivin in de novo acute myeloid leukaemia. British journal of haematology. 2000; 111(1): 196-203.
95. Paydas S. Survivin and aven: two distinct antiapoptotic signals in acute leukemias. Annals of Oncology. 2003; 14(7): 1045-50.
96. Shinozawa I, Inokuchi K, Wakabayashi I, Dan K. Disturbed expression of the anti-apoptosis gene, survivin, and EPR-1 in hematological malignancies. Leukemia research. 2000; 24(11): 965-70.
97. Tamm I, Richter S, Oltersdorf D, Creutzig U, Harbott J, Scholz F, et al. High expression levels of x-linked inhibitor of apoptosis protein and survivin correlate with poor overall survival in childhood de novo acute myeloid leukemia. Clinical Cancer Research. 2004; 10(11): 3737-44.
98. Nakayama K, Kamihira S. Survivin an important determinant for prognosis in adult T-cell leukemia: a novel biomarker in practical hemato-oncology. Leukemia & lymphoma. 2002; 43(12): 2249-55.
99. Carter BZ, Mak DH, Schober WD, Cabreira-Hansen M, Beran M, McQueen T, et al. Regulation of survivin expression through Bcr-Abl/MAPK cascade: targeting survivin overcomes imatinib resistance and increases imatinib sensitivity in imatinib-responsive CML cells. Blood. 2006; 107(4): 1555-63.
100. Nakagawa Y, Yamaguchi S, Hasegawa M, Nemoto T, Inoue M, Suzuki K, et al. Differential expression of survivin in bone marrow cells from patients with acute lymphocytic leukemia and chronic lymphocytic leukemia. Leukemia research. 2004; 28(5): 487-94.
101. Schlette EJ, Medeiros LJ, Goy A, Lai R, Rassidakis GZ. Survivin expression predicts poorer prognosis in anaplastic large-cell lymphoma. Journal of clinical oncology. 2004; 22(9): 1682-8.
102. Xiang X, He Y. [Clinical significance of survivin and caspase-3 expression in diffuse large B-cell lymphoma]. Zhonghua zhong liu za zhi [Chinese journal of oncology]. 2006; 28(4): 298-301.
103. Xiang X, He Y, Li Y, Huang H, Xu F. [Clinical significance of survivin expression in peripheral T-cell lymphoma]. Ai zheng= Aizheng= Chinese journal of cancer. 2006; 25(6): 758-61.
104. Siegel S, Wagner A, Schmitz N, Zeis M. Induction of antitumour immunity using survivin peptide-pulsed dendritic cells in a murine lymphoma model. British journal of haematology. 2003; 122(6): 911-4.
105. Paydas S, Ergin M, Seydaoglu G, Erdogan S, Yavuz S. angiogenic/lymphangiogenic, inflammatory and viral factors in 88 cases with diffuse large B cell lymphoma and review of the literature. Leukemia research. 2009; 33(12): 1627-35. of anti-apoptotic,
106. Paydas S, Ergin M, Erdogan S, Seydaoglu G, Yavuz S, Disel U. Thrombospondin-1 (TSP-1) and Survivin (S) expression in non-Hogkin's lymphomas. Leukemia research. 2008; 32(2): 243-50.
107. Oto OA, Paydas S, Tanriverdi K, Seydaoglu G, Yavuz S, Disel U. Survivin and EPR-1 expression in acute leukemias: prognostic significance and review of the literature. Leukemia research. 2007; 31(11): 1495- 501.
108. Goksel G, Taneli F, Uslu R, Ulman C, Dinc G, Coskun T, Kandiloglu AR. Serum her-2/neu and survivin levels and their relationship to histological parameters in early-stage breast cancer. J Int Med Res. 2007; 35(2): 165-72.
109. Zhang S, Qiang S, Yang W, Jiang J, Ji Z. [Expression of survivin in different stages of carcinogenesis and progression of breast cancer]. Ai zheng= Aizheng= Chinese journal of cancer. 2004; 23(6): 697-700.
110. Kennedy S, O'Driscoll L, Purcell R, Fitz-Simons N, McDermott E, Hill A, et al. Prognostic importance of survivin in breast cancer. British journal of cancer. 2003; 88(7): 1077-83.
111. Gruvberger S, Ringnér M, Chen Y, Panavally S, Saal LH, Borg Å, et al. Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns. Cancer research. 2001; 61(16): 5979-84.
112. Rakha EA, Reis-Filho JS, Ellis IO. Basal-like breast cancer: a critical review. Journal of Clinical Oncology. 2008; 26(15): 2568-81.
113. Perou CM, Sİrlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature. 2000; 406(6797): 747-52.
114. Singh M, Bleile MJ, Shroyer AL, Heinz D, Jarboe EA, Shroyer KR. Analysis of survivin expression in a spectrum of benign to malignant lesions of the breast. Applied Morphology. 2004; 12(4): 296-304. & Molecular
115. Dogu GG, Ozkan M, Ozturk F, Dikilitas M, Er O,
116. Triple-negative Ozturk
117. immunohistochemical correlation with basaloid
118. markers and prognostic value of survivin. Medical
119. oncology. 2010; 27(1): 34-9. breast cancer:
120. Kayaselcuk F, Nursal T, Polat A, Noyan T, Yildirim S, Tarim A, et al. Expresion of Survivin, Bcl-2, P53 and Bax in Breast Carcioma and Ductal Intraepithelial Neoplasia (DIN 1a). Journal of Experimental and Clinical Cancer Research. 2004; 23(1): 105-12.
121. Kucukzeybek Y, Gul MK, Cengiz E, Erten C, Karaca B, Gorumlu G, et al. Enhancement of docetaxel- induced cytotoxicity and apoptosis by all-trans retinoic acid (ATRA) through downregulation of survivin (BIRC5), MCL-1 and LTbeta-R in hormone- and drug resistant prostate cancer cell line, DU-145. Journal of experimental & clinical cancer research. 2008; 27(1): 37.
122. Kucukgoz Gulec U, Gumurdulu D, Guzel AB, Paydas S, Seydaoglu G, Acikalin A, et al. Prognostic importance of survivin, Ki-67, and topoisomerase IIalpha in ovarian carcinoma. Archives of gynecology and obstetrics. 2014; 289(2): 393-8.
123. Çabuk FK, Yiğit S, Demir L, Çakalağaoğlu F, Tarhan O. Correlation of Survivin and MMP9 Expressions with Prognosis and Clinicopathological Parameters in Surface Epithelial Ovarian Carcinomas/Overin Yüzey Epitel Karsinomlarında Survivin ve MMP-9 Ekspresyonlarının Klinikopatolojik Parametrelerle ve Prognozla Korelasyonu. Turkish Journal of Pathology. 2014; 30(1): 30-7.
124. Erbayraktar Z, Aktaş S, Altun Z, Olgun N. Survivin'in Belirlenmesindeki Rolü. Turkiye Klinikleri Journal of Medical Sciences. 2011; 31(5): 1087-93. Direncinin
125. Ösün A, Erbayraktar Z, Erbayraktar S, Samancıoğlu A, Zadeoğulları Z, Akhisarlıoğlu ST, et al. The Effect of Combination on Survivin Gene Expression in Human Glioblastoma Cell Lines. Journal of Neurological Sciences. 2012; 29(3): 518-526. Erythropoietin
126. Gunduz K, Temiz P, Gencoglan G, Inanir I, Catalkaya A. Expression of nuclear factor kappa B and survivin in psoriasis. ISRN dermatology. 2012; Article ID 257059.
127. Ozisik K, Ozisik P, Yildirim E, Misirlioglu M, Tuncer S. Expression of antiapoptotic survivin and aven genes in rat heart tissue after traumatic brain injury. Transplantation proceedings. 2006; 38(9): 2784-7.
128. Abdulmajed MI, Sancak EB, Resorlu B, Al-chalaby GZ. What are the currently available and in development molecular markers for bladder cancer? Will they prove to be useful in the future? Türk Üroloji Dergisi/Turkish Journal of Urology. 2014; 40(4): 228- 32.